Surgery-Induced Cachexia Prevention Systems for Specialized Environments

Publication ID: 24-11857525_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Surgery-Induced Cachexia Prevention Systems for Specialized Environments,” Published Technical Disclosure No. 24-11857525_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857525_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,525.

Summary of the Inventive Concept

The present disclosure relates to novel, specialized systems and methods for preventing surgery-induced cachexia in patients undergoing high-risk surgeries, particularly in extreme weather conditions, disaster relief situations, or for patients with compromised immune systems.

Background and Problem Solved

The original patent disclosed compositions and methods for treating or preventing surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines. However, these compositions and methods may not be suitable for patients undergoing high-risk surgeries or in unique operational environments. The present inventive concept addresses these limitations by providing specialized systems and methods tailored to these specific needs.

Detailed Description of the Inventive Concept

The inventive concept encompasses four main embodiments: 1) a system for treating or preventing surgery-induced cachexia in patients undergoing radical cystoprostatectomy, comprising a specialized immunonutrition supplement specifically formulated for bladder cancer patients; 2) a method for preventing cachexia in patients undergoing surgery in extreme weather conditions, comprising administering a composition packaged in a portable, waterproof container; 3) a kit for treating cachexia in disaster relief situations, comprising a specialized immunonutrition supplement, a water purification system, and instructions for administering the supplement to patients in need; and 4) a system for preventing cachexia in patients undergoing high-risk surgeries, comprising a pre-operative regimen of a specialized immunonutrition supplement, a post-operative regimen of the supplement, and a monitoring system to track patient progress.

Novelty and Inventive Step

The inventive concept's novelty lies in its tailored approach to specific patient populations and operational environments, which is not addressed by the original patent. The inventive step is the combination of specialized immunonutrition supplements, packaging, and administration regimens that address the unique challenges of these environments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include customized immunonutrition supplements for patients with specific medical conditions, such as heart disease or diabetes, or for patients undergoing other types of high-risk surgeries. Additionally, the inventive concept could be adapted for use in space exploration or military operations.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the healthcare industry, particularly in the areas of surgical nutrition, disaster relief, and high-risk surgery. The target market includes hospitals, surgical centers, and disaster relief organizations.

Field of Art

Medical nutrition, immunology, and surgical patient care, specifically focused on cachexia prevention and nutritional supplementation for patients undergoing high-risk surgical procedures

Person of Ordinary Skill (PHOSITA) Profile

A medical nutritionist or clinical researcher with expertise in surgical immunonutrition, understanding of nutritional supplement formulations, and knowledge of patient-specific nutritional interventions

Obviousness Rationale

A person having ordinary skill in the art would recognize that the published technical disclosure represents predictable variations of the source patent's core immunonutrition approach. The PTD extends the original cachexia treatment method by applying the established nutritional supplement composition to specific surgical contexts and patient populations. These variations represent logical adaptations of the existing nutritional intervention strategy to address different clinical scenarios.

Obvious Combinations & Variations

Source Patent Element
Specialized immunonutrition supplement for surgery-induced cachexia
PTD Variation
Adaptation of supplement for specific surgical contexts like disaster relief, extreme weather conditions, and compromised immune systems
Obviousness Reasoning
A PHOSITA would recognize that nutritional interventions can be easily modified for different patient populations using known formulation techniques, representing a predictable design variation
Source Patent Element
Daily dosage ranges for L-arginine, omega-3 fatty acids, and nucleotides
PTD Variation
Maintaining similar dosage ranges while introducing specialized packaging and administration protocols
Obviousness Reasoning
Preserving established nutritional dosage parameters while modifying delivery methods represents an obvious technical adaptation within the known art
Source Patent Element
Treatment method for bladder cancer patients undergoing radical cystoprostatectomy
PTD Variation
Expanding treatment approach to other high-risk surgical scenarios and patient populations
Obviousness Reasoning
Extending a known therapeutic approach to analogous medical contexts is a standard method of developing medical interventions that would be obvious to a skilled practitioner
Source Patent Element
Immunonutrition supplement composition with L-arginine, omega-3 fatty acids, vitamin A, and dietary nucleotides
PTD Variation
Creating specialized kits and systems for supplement administration in challenging environments
Obviousness Reasoning
Developing practical delivery mechanisms for an established nutritional intervention represents a predictable engineering solution within the field
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857525, the published technical disclosure demonstrates that variations in surgical cachexia prevention methods involving specialized immunonutrition supplements represent obvious extensions of the prior art. A person having ordinary skill in the art would recognize that the disclosed variations constitute routine adaptations of known nutritional intervention strategies to specific clinical and environmental contexts, thereby rendering potential patent claims obvious and unpatentable.

Original Patent Information

Patent NumberUS 11,857,525
TitleTreatment or prevention of surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines
Assignee(s)SOCIÉTÉ DES PRODUITS NESTLÉ S.A.